⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19380626 | 1.00 | — | — | |
| SCHEMBL3399729 | 0.81 | TSHR (0.44) | — | |
| SCHEMBL3399731 | 0.81 | TSHR (0.44) | — | |
| SCHEMBL3975815 | 0.78 | — | — | |
| SCHEMBL3975808 | 0.78 | — | — | |
| SCHEMBL18265649 | 0.75 | — | — | |
| SCHEMBL19403915 | 0.75 | — | — | |
| SCHEMBL11578116 | 0.75 | TSHR (0.39) | — | |
| SCHEMBL11578112 | 0.75 | TSHR (0.39) | — | |
| SCHEMBL3806452 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745341-B2 | Tubulysins and processes for preparing | ENDOCYTE, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160108085-A1 | TUBULYSINS AND PROCESSES FOR PREPARING | ENDOCYTE INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-9187521-B2 | Tubulysins and processes for preparing | ENDOCYTE, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2209374-B1 | TUBULYSINS AND PROCESSES FOR PREPARING | ENDOCYTE INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20100240701-A1 | TUBULYSINS AND PROCESSES FOR PREPARING | ENDOCYTE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2209374-A1 | TUBULYSINS AND PROCESSES FOR PREPARING | Endocyte, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009055562-A1 | TUBULYSINS AND PROCESSES FOR PREPARING | ENDOCYTE, INC. (US) | 2009-04-30 | — | — | WO | disclosed |